The GRANDIOSA study (‘Growth, ALlergy and NeuroDevelopment in Infants On hydrolySed formulA’) started in late 2022 and is conducted in Umeå and Malmö.
The purpose of the study is to determine the effects of two novel protein hydrolysates on infants’ growth, neurological development, allergies, gastrointestinal symptoms and other health outcomes. GRANDIOSA is a blinded, placebo-controlled, randomized clinical trial to test two new partially hydrolysed infant formulas. The children will follow their assigned regimen until they are five months old and there will be regular follow-up of the children until they are one year old.
Digital meetings are held regularly and a first IRL meeting was held in Umeå on 20 October 2023. This has now been followed by a meeting at the Clinical Research Centre in Malmö on Friday 8 November 2024.
Participants at the meeting were:
From Umeå: Magnus Domellöf (PI), Christina West (co-PI), Sara Olivecrona (PhD student), Gunilla Strinnholm (research nurse)
From Malmö: Pia Karlsland Åkeson (PI), Eleni Kordi (PhD student), Ingrid Avenäs and Filippa Wikström (research nurses)
From Arla Foods Ingredients: Lotte Neergaard Jacobsen and Anne Staudt Kvistgaard
The morning had a number of presentations of relevance to the study. Sara and Eleni presented current study data and Filippa and Ingrid showed charts of the recruitment.
There were also results presented from a couple of other studies; Magnus presented data from NorthPop and Pia presented results from the ALFoNS study.
After lunch the pediatric psychologists involved in the study attended to talk about Bayley 4 testing and there were opportunities for group discussions.
“This was a very productive and rewarding day with great presentations and discussions” said Magnus Domellöf, PI for the study in Umeå.
Meeting participants from left to right in the photo: Sara, Pia, Lotte, Gunilla, Anne, Magnus, Eleni, Filippa, Ingrid, Christina